Loxo Oncology Inc (LOXO) Expected to Announce Earnings of -$1.27 Per Share

Wall Street analysts forecast that Loxo Oncology Inc (NASDAQ:LOXO) will post ($1.27) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Loxo Oncology’s earnings, with the lowest EPS estimate coming in at ($1.48) and the highest estimate coming in at ($1.16). Loxo Oncology posted earnings of ($1.28) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 0.8%. The business is scheduled to announce its next earnings report on Tuesday, March 6th.

According to Zacks, analysts expect that Loxo Oncology will report full-year earnings of ($5.91) per share for the current financial year, with EPS estimates ranging from ($6.15) to ($5.74). For the next fiscal year, analysts forecast that the business will report earnings of ($5.10) per share, with EPS estimates ranging from ($6.31) to ($4.45). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Loxo Oncology.

Several equities research analysts recently commented on LOXO shares. BidaskClub raised shares of Loxo Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. William Blair started coverage on shares of Loxo Oncology in a report on Tuesday, November 28th. They issued an “outperform” rating for the company. Citigroup cut their price target on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, November 16th. Finally, JMP Securities raised shares of Loxo Oncology from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $77.18 to $95.00 in a report on Tuesday, November 14th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Loxo Oncology currently has a consensus rating of “Buy” and a consensus target price of $90.57.

Loxo Oncology (NASDAQ:LOXO) traded up $2.27 during trading hours on Tuesday, hitting $96.40. 217,769 shares of the stock traded hands, compared to its average volume of 319,785. The stock has a market cap of $2,935.67, a price-to-earnings ratio of -16.48 and a beta of 2.57. Loxo Oncology has a 52-week low of $39.05 and a 52-week high of $106.40.

In other news, Director Orbimed Advisors Llc sold 270,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $74.26, for a total transaction of $20,050,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $75.00, for a total transaction of $37,500,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 1,628,396 shares of company stock valued at $125,989,430. 27.80% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. grew its holdings in shares of Loxo Oncology by 31.3% during the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 419 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Loxo Oncology by 3.8% during the second quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 592 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Loxo Oncology by 2.9% during the 3rd quarter. New York State Common Retirement Fund now owns 25,097 shares of the biopharmaceutical company’s stock valued at $2,312,000 after acquiring an additional 700 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Loxo Oncology by 3.1% during the 3rd quarter. California State Teachers Retirement System now owns 36,594 shares of the biopharmaceutical company’s stock valued at $3,371,000 after acquiring an additional 1,094 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Loxo Oncology during the 3rd quarter valued at about $122,000.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/06/loxo-oncology-inc-loxo-expected-to-announce-earnings-of-1-27-per-share-2.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Get a free copy of the Zacks research report on Loxo Oncology (LOXO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply